-
Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcino
prnasia
June 28, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases today announced that the ...
-
Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous No
prnasia
June 04, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company jointly ...
-
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
prnasia
April 13, 2021
Innovent Biologics, Inc. announced with Eli Lilly and Company that the results of the Phase 3 ORIENT-3 study were released in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.
-
Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress
prnasia
March 30, 2021
Innovent Biologics, Inc. announced its financial results for the year ended December 31, 2020 and the corporate progress. In 2020, the Company achieved total revenue of RMB 3843.8 million.
-
Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma
prnasia
February 09, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the first patient has ...
-
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small
prnasia
February 03, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company, today ...
-
Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer
prnasia
December 11, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first ...
-
TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatme
prnasia
September 28, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases ...
-
Eli Lilly expands Tyvyt collaboration with Innovent Biologics
pharmaceutical-technology
August 20, 2020
Eli Lilly has agreed to a global expansion of its strategic collaboration with Innovent Biologics for Tyvyt (sintilimab injection), which the partners jointly develop in China.
-
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
prnasia
January 13, 2020
The safety profile of sintilimab in this trial was consistent with previously reported studies, and no new safety signals were identified.